



Are you a teenager between the ages of 12 and 18 with type 1 diabetes (T1D)? Consider participating in our study.

What is the ATTEMPT study?

ATTEMPT is a 22-week clinical trial that aims to determine the safety and effectiveness of a medication called **Dapagliflozin** on managing blood glucose and on improving kidney function in adolescents ages 12 to 18 with type 1 diabetes.

What are Dapagliflozin and SGLT2 inhibitors?

SGLT2 inhibitors (SGLT2i) such as Dapagliflozin are a class of oral medications used with insulin that reduce glucose from your blood from being absorbed by your kidney. As a result, glucose from your blood is released in your urine.

By doing so, SGLT2 inhibitors can improve blood sugars, increase time in range and decrease kidney pressure, called hyperfiltration (see **Benefits** below).

Why are we doing this study?

High blood sugars during adolescence can lead to an increased risk of diabetes-related complications.

Dapagliflozin, like other SGLT2 inhibitors, has been studied in adults, and may prevent long-term diabetes-related complications by lowering blood sugars, and relieving pressure on the kidneys.

Given these benefits, we are trying to study how well this therapy can be applied in adolescents with T1D.

What does joining the study entail?

The Basics:

- 5 in-person visits over 22 weeks
- You will be randomly assigned to the Dapagliflozin group, or the placebo group (a pill that contains no active medicine)

While you are in the study, you will:

- Keep taking insulin
- Wear a continuous glucose monitor (CGM)
- Test for blood ketones
- Report any adverse events

What are the Risks and Benefits of joining the study?

Benefits

Adult studies on SGLT2i in T1D have shown these medications can help lower HbA1c, insulin dose and weight. They can also help increase time in target blood sugar range. By acting on the kidney, SGLT2i can help prevent long term damage to the kidneys.

Risks

Studies in adults linked SGLT2i with a risk of low blood sugars. Low fluids (dehydration) and more frequent use of the bathroom were also reported. In rare cases, urinary tract infections and Diabetes keto acidosis (DKA) were reported.

Will I be compensated?

Study participants will be compensated and provided support for costs associated with travel or parking.

Interested in participating?

Would like more information about the ATTEMPT study?

We would like to hear from you! Please contact:

By telephone at 416-813-7654 ext. 204517 or by email at attempt.study@sickkids.ca

